New York, USA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Acute Ocular Pain Market to Witness Positive Growth by 2032, Examines DelveInsight | Key Players - Formosa, Surface Ophthalmics, Sun Pharma, Ocular Therapeutix, Kala Pharmaceuticals, Bausch & Lomb
The acute ocular pain market is expected to grow significantly in the coming years by factors like an increase in the patient pool, and the expected entry of emerging therapies.
DelveInsight’s Acute Ocular Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute ocular pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Acute Ocular Pain Market Report
- As per DelveInsight’s analysis, the acute ocular pain market is anticipated to grow at a significant CAGR by 2032.
- As per the DelveInsight estimates, in the year 2021, the total cases of acute ocular pain were ~10 million in the 7MM, which might increase by 2032.
- Leading acute ocular pain companies such as Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, and others currently working in the acute ocular pain market.
- Some of the key therapies for acute ocular pain treatment include APP13007, SURF-201, SDN-037, DEXTENZA (dexamethasone ophthalmic insert), INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121), BROMSITE (bromfenac ophthalmic solution), LOTEMAX SM (loteprednol etabonate ophthalmic gel), PROLENSA (bromfenac ophthalmic solution) 0.07%, and others.
Discover which therapies are expected to grab the major acute ocular pain market share @ Acute Ocular Pain Market Report
Acute Ocular Pain Overview
Acute ocular pain, commonly referred to as sudden and severe eye pain, is a distressing condition that demands prompt attention. It can originate from various causes, ranging from mild to severe, and requires careful evaluation for accurate diagnosis and timely treatment. The causes of acute ocular pain are diverse, encompassing both external and internal factors.
Recognizing the symptoms of acute ocular pain is crucial for appropriate management. Patients often report sensations of intense discomfort, often described as sharp, stabbing, or burning. Redness, tearing, sensitivity to light, blurred vision, and even changes in visual perception may accompany the pain. Importantly, any sudden decrease in vision or the appearance of halos around lights warrants immediate medical attention.
Diagnosis of the underlying cause involves a comprehensive approach. An eye care professional will begin with a thorough medical history, assessing recent trauma, exposure to irritants, or systemic illnesses. A detailed eye examination, including visual acuity testing, pupillary evaluation, and slit-lamp microscopy, aids in identifying corneal injuries, conjunctival infections, or uveal inflammation. In cases of suspected acute glaucoma, measuring intraocular pressure is crucial.
Acute Ocular Pain Epidemiology Segmentation
The acute ocular pain epidemiology section provides insights into the historical and current acute ocular pain patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The acute ocular pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Number of Cases of Several Eye Disorders
- Number of Cases of Acute Ocular Pain in Major Eye Disorders
Download the report to understand which factors are driving acute ocular pain epidemiology trends @ Acute Ocular Pain Epidemiological Insights
Acute Ocular Pain Treatment Market
Acute ocular pain treatment involves swift and targeted interventions to alleviate sudden and severe eye discomfort. Prompt evaluation by a qualified eye care professional is essential to identify the underlying cause, which could range from minor issues like corneal abrasions or foreign body sensations to more serious conditions such as acute angle-closure glaucoma or uveitis. Once the cause is determined, the most suitable course of action is decided. Acute ocular pain treatment strategies may encompass a range of approaches, including topical or oral pain relievers to provide immediate relief from discomfort. Anti-inflammatory medications might be prescribed to reduce swelling and irritation in the eye tissues. Lubricating eye drops can be employed to ensure the ocular surface remains adequately moist and comfortable. In specific cases, more specialized treatments such as corticosteroid eye drops may be recommended to address inflammatory conditions.
In certain urgent situations, surgical intervention might be required to alleviate the source of the pain, such as in cases of severe trauma, infection, or intraocular pressure abnormalities. Laser procedures could be used to manage conditions like acute angle-closure glaucoma. The treatment plan will depend on the severity of the pain, the underlying cause, and the patient’s overall eye health. The primary goal of acute ocular pain treatment is to swiftly alleviate pain, reduce inflammation, and safeguard the health and well-being of the patient’s eyesight. Timely and appropriate interventions not only provide relief from discomfort but also contribute to preventing potential complications that could threaten vision. It’s crucial for individuals experiencing acute ocular pain to seek professional medical attention promptly to ensure the best possible outcome for their eye health.
To know more about acute ocular pain treatment, visit @ Acute Ocular Pain Treatment Drugs
Key Acute Ocular Pain Therapies and Companies
- APP13007: Formosa Pharmaceuticals
- SURF-201: Surface Ophthalmics
- SDN-037: Sun Pharma Advanced Research Company Ltd (SPARC)
- DEXTENZA (dexamethasone ophthalmic insert): Ocular Therapeutix
- INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121): Kala Pharmaceuticals
- BROMSITE (bromfenac ophthalmic solution): Sun Pharmaceutical
- LOTEMAX SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb
- PROLENSA (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb
Learn more about the FDA-approved drugs for acute ocular pain @ Drugs for Acute Ocular Pain Treatment
Acute Ocular Pain Market Dynamics
The acute ocular pain market dynamics reflect a complex interplay of factors that influence the diagnosis, treatment, and management of this condition. With advancements in medical technology, there has been a growing emphasis on accurate and timely diagnosis, driving the demand for innovative diagnostic tools and techniques. Pharmaceutical companies are striving to develop targeted and effective medications to alleviate acute ocular pain, leading to a surge in research and development activities.
Additionally, shifting demographics and an aging population contribute to an increased prevalence of ocular conditions, consequently propelling the demand for pain relief solutions. The market is also witnessing a trend towards personalized medicine, where treatment approaches are tailored to individual patient needs. Moreover, the evolving regulatory landscape and healthcare policies play a pivotal role in shaping acute ocular pain market strategies and access to therapies. As patient awareness and expectations continue to rise, healthcare providers and industry stakeholders must adapt and collaborate to address the multifaceted challenges within the acute ocular pain market.
Despite the promising dynamics, the acute ocular pain market also faces several significant barriers that impact its growth and development. One of the primary challenges is the regulatory landscape, which can vary widely across different regions and countries. Another barrier lies in the complex nature of ocular pain itself. This complexity can lead to misdiagnoses or delayed diagnoses, affecting the timely administration of appropriate treatments. The high cost of research and development for ocular pain therapies poses a considerable obstacle, especially for smaller companies with limited resources. This financial burden can impede innovation and hinder the entry of new players into the acute ocular pain market.
Additionally, patient adherence to treatment plans can be challenging, particularly when it comes to ocular pain management. Factors such as discomfort from eye drops, frequent dosing, and the need for consistent follow-up can lead to non-compliance, affecting treatment efficacy. Market competition, while driving innovation, can also create challenges. Established players with strong market presence and brand recognition may overshadow newer entrants, making it harder for innovative solutions to gain traction. This can sometimes limit the availability and adoption of advanced ocular pain treatments.
| Acute Ocular Pain Report Metrics | Details |
| Study Period | 2019–2032 |
| Acute Ocular Pain Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Acute Ocular Pain Companies | Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, and others |
| Key Acute Ocular Pain Therapies | APP13007, SURF-201, SDN-037, DEXTENZA (dexamethasone ophthalmic insert), INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121), BROMSITE (bromfenac ophthalmic solution), LOTEMAX SM (loteprednol etabonate ophthalmic gel), PROLENSA (bromfenac ophthalmic solution) 0.07%, and others |
Scope of the Acute Ocular Pain Market Report
- Therapeutic Assessment: Acute Ocular Pain current marketed and emerging therapies
- Acute Ocular Pain Market Dynamics: Attribute Analysis of Emerging Acute Ocular Pain Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Acute Ocular Pain Market Access and Reimbursement
Discover more about acute ocular pain drugs in development @ Acute Ocular Pain Clinical Trials
Table of Contents
| 1. | Acute Ocular Pain Market Key Insights |
| 2. | Acute Ocular Pain Market Report Introduction |
| 3. | Acute Ocular Pain Market Overview at a Glance |
| 4. | Acute Ocular Pain Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Acute Ocular Pain Treatment and Management |
| 7. | Acute Ocular Pain Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Acute Ocular Pain Marketed Drugs |
| 10. | Acute Ocular Pain Emerging Drugs |
| 11. | Seven Major Acute Ocular Pain Market Analysis |
| 12. | Acute Ocular Pain Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Acute Ocular Pain Epidemiology
Acute Ocular Pain Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted acute ocular pain epidemiology in the 7MM.
Acute Ocular Pain And Inflammation Pipeline
Acute Ocular Pain And Inflammation Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute ocular pain and inflammation companies including Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, Formosa Pharmaceuticals, Aldeyra Therapeutics, Sylentis, among others.
Acute Ocular Pain And Inflammation Market
Acute Ocular Pain And Inflammation Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute ocular pain and inflammation companies, including Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, Formosa Pharmaceuticals, Aldeyra Therapeutics, Sylentis, among others.
Acute Ocular Pain And Inflammation Epidemiology
Acute Ocular Pain And Inflammation Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted acute ocular pain and inflammation epidemiology in the 7MM.
Cataract Surgery Devices Market
Cataract Surgery Devices Market Insight, Competitive Landscape, and Market Forecast – 2028 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cataract surgery devices companies including Alcon Inc (Novartis), Johnson & Johnson Vision Care, Inc., NIDEK CO., LTD, ZEISS Group, Bausch & Lomb Incorporated, among others.
Ophthalmic Viscoelastic Devices Market
Ophthalmic Viscoelastic Devices Market Insight, Competitive Landscape, and Market Forecast – 2028 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key ophthalmic viscoelastic devices companies including Bausch Health Companies Inc., Eyekon Medical Inc., Bohus BioTech AB, Carl Zeiss Meditec AG, CIMA Technology Inc., Johnson & Johnson Vision Care, Inc., Alcon Inc., among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
